Published in Women's Health Weekly, March 29th, 2012
"Consecutive women undergoing PerigeeA ® or Anterior ProliftA ® for symptomatic stage 2 or greater anterior vaginal prolapse were prospectively evaluated. Main outcome measures included objective and subjective success rates, perioperative outcomes, patient satisfaction, and complications. One hundred and six women (Prolift, 52; Perigee, 54) completed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.